Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Even though many medical organizations recommend discussions between patients and their doctors before testing of individuals for risk of prostate cancer, there are few hard data about how primary care physicians (PCPs) actually apply thee guidelines to promote informed decision making for prostate cancer testing.
Filed under: Diagnosis, Risk | Tagged: DRE, PCP, primary care physician, PSA, screening, testing | Leave a Comment »
Dendreon researchers have presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 trial suggesting that sipuleucel-T (Provenge) induces durable responses that can be maintained following an immune boost. These early data from the PROTECT trial were presented Sunday at the annual meeting of the American Association for Cancer Research [...]
Filed under: Drugs in development, Management, Treatment | Tagged: androgen-dependent, Provenge, sipleucel-T | Leave a Comment »
Dana Jennings isn’t the only member if his family with a health problem. See his article (“A Bond Shaped by Illness, but Not Defined by It“) on the New York Times Well blog today.
Filed under: Living with Prostate Cancer | Tagged: Dana Jennings | Comments Off
A multi-center analysis involving nearly 1,500 veterans has suggested that those exposed to Agent Orange were at higher risk for recurrence after radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Agent Orange, progression, radical prostatectomy, risk | Leave a Comment »
Shanghai-born writer J. G. Ballard, who started out as a writer of such avant garde science fiction as The Drowned World and The Crystal World but went on to produce the widely read novels Empire of the Sun and Crash, has died of prostate cancer. He was diagnosed with advanced disease in 2006.
Filed under: Uncategorized | Tagged: Ballard | 1 Comment »
According to an article in Forbes magazine, information about a Phase I clinical trial of “anti-PSMA designer T cells” in prostate cancer was presented today at the American Association for Cancer Research (AACR) meeting in Denver.
Filed under: Drugs in development | Tagged: anti-PSMA, immunotherapy, T-cell | Leave a Comment »
The reports discussed below deal with: Positron emission tomography in prostate cancer management HIFU and cryotherapy in focal therapy for prostate cancer Does a prior TURP affect outcomes to radical prostatectomy?
Filed under: Management, Treatment, Uncategorized | Tagged: cryotherapy, HIFU, high-intensity focuse ultrasound, outcome, PET, positron emission tomography, transurethral resection, TURP | Leave a Comment »
Many years ago (in late 1995 I believe), relatively soon after we had started the original version of this web service, I was contacted by Dr. Steven Bova from Johns Hopkins. He was trying to identify living prostate cancer patients willing to donate their bodies to research at the time of their deaths. The core [...]
Filed under: Uncategorized | 2 Comments »
Today’s news reports deal with: Active surveillance management strategies and outcomes to date Life expectancy and the appropriateness of treatment Penile rehabilitation post-surgery Testosterone replacement therapy in prostate cancer patients
Filed under: Management, Treatment, Uncategorized | Tagged: active surveillance, life expectancy, penile rehabilitation, testosterone replacement, Treatment, TRT | Leave a Comment »
The annual meeting of the American Association for Cancer Research starts tomorrow in Denver, Colorado.
Filed under: Drugs in development, Prevention | Tagged: AACR, ASCO, finasteride | Leave a Comment »
In today’s news reports we address: Prediction of freedom from biochemical failure after brachytherapy Prediction of probability of unilateral prostate cancer in men eligible for focal therapy Health-related quality of life 5 years after radiotherapy + androgen deprivation Androgen receptor activity “signatures” in men with CRPC
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: androgen receptor activity, brachytherapy, CRPC, dose, focal therapy, HRQOL, outcome, quality of life, signature, unilateral | Leave a Comment »
An article just published online in the UroToday International Journal appears to be the first prospective study to indicate, in a large group of patients, that 3D color Döppler ultrasound imaging (3D-CDI) can diagnose the presence of prostate cancer with an accuracy close to that of prostate biopsy.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: 3D color Döppler ultrasound, Diagnosis | 5 Comments »
Bivalaqua and colleagues from Johns Hopkins Medical Center have reviewed progress in functional and oncologic outcomes after prostatectomy made during the past few decades.
Filed under: Management, Treatment | Tagged: laparoscopic, open, robot-assisted, surgery | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site